

POLICY: Enzyme Replacement Therapy – Elaprase Utilization Management Medical Policy

- Elaprase® (idursulfase intravenous infusion – Shire Human Genetic Therapies)

EFFECTIVE DATE: 1/1/2021

LAST REVISION DATE: 04/22/2026

COVERAGE CRITERIA FOR: All Aspirus Medicare Plans

OVERVIEW

Elaprase, human iduronate-2-sulfatase (idursulfase), is indicated for **Hunter syndrome (Mucopolysaccharidosis type II [MPS II])**.¹

Disease Overview

MPS II or Hunter syndrome, is a rare, X-linked lysosomal storage disorder characterized by a deficiency of iduronate-2-sulfatase leading to the accumulation of glycosaminoglycans dermatan sulfate and heparan sulfate.^{2,3} Males are almost exclusively affected, although a small number of case reports describe females with Hunter syndrome.^{3,4} The onset, progression, and severity of MPS II is variable.^{2,4} Most of the patients with MPS II have a severe form with neurologic involvement leading to cognitive impairment and neurologic regression.^{3,4} Other manifestations of Hunter syndrome include coarse facial features, hepatosplenomegaly, cardiac and respiratory disease, short stature, and stiff joints and contractures.^{2,3} Definitive diagnosis of MPS II is established by demonstrating deficient iduronate-2-sulfatase activity in leukocytes, fibroblasts, serum, or plasma; or mutations in the iduronate-2-sulfatase gene.^{2,5} Treatment of MPS II consists of enzyme replacement therapy with Elaprase.^{2,4,6} Hematopoietic stem cell transplantation has not demonstrated clear neurological benefit to date and is not recommended for MPS II due to the high rate of morbidity and mortality associated with this therapy.^{2,4}

Dosing Information

The recommended dosage regimen of Elaprase is 0.5 mg per kg of body weight administered once weekly as an intravenous infusion.

Guidelines

An expert consensus practice resource from the American College of Medical Genetics and Genomics was published in 2020; a recommendation was made to initiate treatment with Elaprase at the time of diagnosis and prior to symptom onset for individuals predicted to have severe MPS II, as well as for individuals with symptoms regardless of the predicted severity.⁶ The expert panel also recommended against presymptomatic treatment for individuals expected to have non-neuronopathic Hunter's syndrome; however, this recommendation is complicated by genetic variability and uncertainty in predicting clinical phenotype.

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Elaprase. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Elaprase as well as the monitoring required for adverse events and long-term efficacy, approval requires Elaprase to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Elaprase is recommended in those who meet the following criteria:

FDA-Approved Indication

-
- 1. Mucopolysaccharidosis Type II (Hunter Syndrome).** Approve for 1 year if the patient meets BOTH of the following (A and B):
 - A)** The diagnosis is established by ONE of the following (i or ii):
 - i.** Patient has a laboratory test demonstrating deficient iduronate-2-sulfatase activity in leukocytes, fibroblasts, serum, or plasma; OR
 - ii.** Patient has a molecular genetic test demonstrating an iduronate-2-sulfatase gene variant; AND
 - B)** Elaprase is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

Dosing. Each dose must not exceed 0.5 mg/kg administered intravenously no more frequently than once a week.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Elaprase is not recommended in the following situations:

- 1. Concomitant Use of Elaprase with Avlayah™ (tvidenofusp alfa-eknm).** Avlayah is indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.⁷ Avlayah has a *Limitation of Use* that it is not recommended for use in combination with other enzyme replacement therapies.
- 2.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Elaprase® intravenous infusion [prescribing information]. Cambridge, MA: Takeda; February 2025.
2. Scarpa M, Almassy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. *Orphanet J Rare Dis.* 2011;6:72.
3. Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. *Pediatrics.* 2009;124:e1228-e1239.
4. Giugliani R, Federhen A, Munoz Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. *Genet Mol Biol.* 2010;33:589-604.
5. D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis type II: One hundred years of research, diagnosis, and treatment. *Int J Mol Sci.* 2020;21:E1258.
6. McBride KL, Berry SA, Braverman N; ACMG Therapeutics Committee. Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2020 Nov;22(11):1735-1742.
7. Avlayah™ intravenous infusion [prescribing information]. South San Francisco, CA: Denali; March 2026.

HISTORY

| Type of Revision | Summary of Changes | Review Date |
|--------------------|---|-------------|
| Annual Revision | No criteria changes. | 04/12/2023 |
| Annual Revision | Mucopolysaccharidosis Type II (Hunter Syndrome): For diagnosis confirmed by molecular genetic testing, the term “mutation” was rephrased to “variant”. | 04/24/2024 |
| Aspirus P&T Review | Policy reviewed and approved by Aspirus P&T committee. Annual review process | 09/16/2024 |
| Annual Revision | No criteria changes. | 04/16/2025 |
| Aspirus P&T Review | Policy reviewed and approved by Aspirus P&T committee. Annual review process | 09/15/2025 |
| Annual Revision | Conditions Not Recommended for Approval: Concomitant use of Elaprase with Avlayah™ (tvidenofusp alfa-eknm) was added. | 04/22/2026 |